Protalix BioTherapeutics (PLX) Accumulated Expenses (2011 - 2026)

Protalix BioTherapeutics' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 73.82% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 73.82% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 75.87% from the prior year.
• Accumulated Expenses improved to $2.4 million in Q1 2026 per PLX's latest filing, from $2.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.6 million in Q4 2024 and bottomed at $745000.0 in Q3 2025.
• The 4-year median for Accumulated Expenses is $2.3 million (2025), against an average of $3.9 million.
• Across the five-year window, Accumulated Expenses jumped 496.14% in 2024 and sank 75.87% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $1.6 million in 2023, then soared by 496.14% to $9.6 million in 2024, then sank by 75.87% to $2.3 million in 2025, then climbed by 6.02% to $2.4 million in 2026.
• Per Business Quant, the three latest PLX Accumulated Expenses figures stand at $2.4 million (Q1 2026), $2.3 million (Q4 2025), and $745000.0 (Q3 2025).